Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MTFB
CUSIPN/A
Phone212-210-6248
Debt
Debt-to-Equity Ratio-4.25
Current Ratio1.31
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-42.37
Forward P/E Ratio-5.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-11.84
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees8
Outstanding Shares14,830,000
Market Cap$123.06 million
MOTIF BIO PLC/S (NASDAQ:MTFB) Frequently Asked Questions
What is MOTIF BIO PLC/S's stock symbol?
MOTIF BIO PLC/S trades on the NASDAQ under the ticker symbol "MTFB."
What price target have analysts set for MTFB?
5 brokerages have issued twelve-month price objectives for MOTIF BIO PLC/S's stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate MOTIF BIO PLC/S's share price to reach $19.50 in the next year. This suggests a possible upside of 142.2% from the stock's current price. View Analyst Price Targets for MOTIF BIO PLC/S.
What is the consensus analysts' recommendation for MOTIF BIO PLC/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MOTIF BIO PLC/S in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MOTIF BIO PLC/S.
What are Wall Street analysts saying about MOTIF BIO PLC/S stock?
Here are some recent quotes from research analysts about MOTIF BIO PLC/S stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We employ a risk- adjusted net present value (rNPV) approach that yields $600M for iclaprim—with a 90% probability of success, 16% discount rate and 40% effective tax rate—and a price per share of $32.00 based on about 19M American Depositary Shares (ADSs) outstanding as of mid-2019." (8/14/2018)
- 2. WBB Securities analysts commented, "We believe there is a critical need for novel antibiotics. Based on the clinical data provided through Phase 3 studies REVIVE-1 and REVIVE-2, iclaprim has a high probability of obtaining FDA approval. However, success for MTFB is not just manifest through clinical proof, but also through negotiating the vagaries of reimbursement, gaining clinician acceptance, hospital inclusion and inclusion in the overall patient care paradigm. Additionally, we remain concerned about the resourcing path regarding the future of iclaprim. We are therefore initiating our coverage of MTFB with a Sell rating and a 12- month price target of $7.00." (12/29/2017)
Who are some of MOTIF BIO PLC/S's key competitors?
Some companies that are related to MOTIF BIO PLC/S include Akebia Therapeutics (AKBA), Kezar Life Sciences (KZR), Adamas Pharmaceuticals (ADMS), Stemline Therapeutics (STML), Progenics Pharmaceuticals (PGNX), Aurinia Pharmaceuticals (AUPH), ArQule (ARQL), OptiNose (OPTN), Depomed (DEPO), BioSpecifics Technologies (BSTC), Corium International (CORI), Forty Seven (FTSV), Abeona Therapeutics (ABEO), Beyondspring (BYSI) and TG Therapeutics (TGTX).
Who are MOTIF BIO PLC/S's key executives?
MOTIF BIO PLC/S's management team includes the folowing people:
- Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
- Mr. Jonathan E. Gold, CFO & Exec. Director (Age 45)
- Dr. David B. Huang, Chief Medical Officer (Age 43)
- Mr. Robert Dickey IV, Advisor (Age 62)
- Liam O'Donoghue, Company Sec.
When did MOTIF BIO PLC/S IPO?
(MTFB) raised $17 million in an initial public offering (IPO) on Friday, November 18th 2016. The company issued 2,400,000 shares at a price of $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.
How do I buy shares of MOTIF BIO PLC/S?
Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MOTIF BIO PLC/S's stock price today?
One share of MTFB stock can currently be purchased for approximately $8.05.
How big of a company is MOTIF BIO PLC/S?
MOTIF BIO PLC/S has a market capitalization of $123.06 million. The company earns $-44,810,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. MOTIF BIO PLC/S employs 8 workers across the globe.
What is MOTIF BIO PLC/S's official website?
How can I contact MOTIF BIO PLC/S?
MOTIF BIO PLC/S's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]
MarketBeat Community Rating for MOTIF BIO PLC/S (NASDAQ MTFB)
MarketBeat's community ratings are surveys of what our community members think about MOTIF BIO PLC/S and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
